| ID | 119178 |
| 著者 |
Yamashita, Hisako
Kanaiso Hospital
Kato, Yoshinobu
Kanaiso Hospital
Ogura, Katsunori
Kanaiso Hospital
Kato, Yoshikane
Kanaiso Hospital
|
| キーワード | Vildagliptin / Metformin (Equmet)
Imeglimin (Twymeeg)
Gastro-Intestinal Adverse Effects
Trials of Imeglimin for Efficacy and Safety
Vildagliptin Efficacy in Combination with Metformin for Early Treatment of Type 2 Diabetes
|
| 資料タイプ |
学術雑誌論文
|
| 抄録 | Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D).
Case Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet. Results: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs). Discussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness. |
| 掲載誌名 |
Asploro Journal of Biomedical and Clinical Case Reports
|
| ISSN | 25820370
|
| 出版者 | Asploro
|
| 巻 | 6
|
| 号 | 2
|
| 開始ページ | 69
|
| 終了ページ | 75
|
| 発行日 | 2023-04-14
|
| 権利情報 | This is an open-access article distributed under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
|
| 出版社版DOI | |
| 出版社版URL | |
| フルテキストファイル | |
| 言語 |
eng
|
| 著者版フラグ |
出版社版
|
| 部局 |
医学系
|
